Behavioural Pharmacology

Changes in gut microbiota during development of compulsive checking and locomotor sensitization induced by chronic treatment with the dopamine agonist quinpirole --Manuscript Draft--

Manuscript Number:	BP-17-110R1
Full Title:	Changes in gut microbiota during development of compulsive checking and locomotor sensitization induced by chronic treatment with the dopamine agonist quinpirole
Article Type:	Research Report
Keywords:	Compulsive checking behavior; locomotor sensitization; quinpirole; gut microbiota; Lachnospiraceae; energy metabolism; hyperactivity; security motivation system; animal model; obsessive-compulsive disorder
Corresponding Author:	Henry Szechtman McMaster University Hamilton, FRANCE
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	McMaster University
Corresponding Author's Secondary Institution:	
First Author:	Tony Jung
First Author Secondary Information:	
Order of Authors:	Tony Jung
	Paul S Jung
	Lucshman Raveendran
	Yasamin Farbod
	Anna Dvorkin-Gheva
	Boris Sakic
	Michael G Surette
	Henry Szechtman
Order of Authors Secondary Information:	
Manuscript Region of Origin:	CANADA
Abstract:	Chronic treatment of rats with the D2/D3 dopamine agonist quinpirole induces compulsive checking (proposed as animal model of obsessive-compulsive disorder; OCD) and locomotor sensitization. The mechanisms by which chronic quinpirole produces those behavioral transformations are not known. Here we examined whether changes in gut microbiota play a role in these behavioral phenomena by monitoring the development of compulsive checking and locomotor sensitization at the same time as measuring the response of gut microbiota to chronic quinpirole injections. Two groups of rats received 9 injections of saline (n=16) or quinpirole (n=15; 0.25 mg/kg), at weekly intervals for the first 5 weeks and then 2 injections per week until end of treatment. After each injection, rats were placed on a large open field for 55 min and their behavior was video recorded for subsequent analysis. Fecal matter was collected after each trial and frozen for bacterial community profiling of the 16S rRNA gene using paired end reads of the V3 region. Results indicated that the induction of locomotor sensitization and compulsive checking was accompanied by changes in several communities of bacteria belonging to the order Clostridiales (class Clostridia, phylum Firmicutes), and predominantly in Lachnospiraceae and Ruminococcaceae families of bacteria. It is suggested that changes in these microbes may serve to support the energy utilization requirements of compulsive checking and OCD.

CHANGES IN GUT MICROBIOTA DURING DEVELOPMENT OF COMPULSIVE CHECKING AND LOCOMOTOR SENSITIZATION INDUCED BY CHRONIC TREATMENT WITH THE DOPAMINE AGONIST QUINPIROLE

```
TONY JUNG, PAUL S JUNG, LUCSHMAN RAVEENDRAN, YASAMIN FARBOD, ANNA DVORKIN-GHEVA, BORIS SAKIC, MICHAEL G SURETTE AND HENRY SZECHTMAN<sup>§</sup>
```

Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada

Running Title: Quinpirole-induced changes in gut microbiota Figures: 3; Tables: 2; Abstract: 218 words

§Correspondence:
Dr. H Szechtman
Department of Psychiatry and Behavioral Neurosciences
McMaster University
1280 Main Street West
Health Science Centre, Room 4N82
Hamilton, Ontario
CANADA L8S 4K1
Tel: (905) 525-9140 ext 22201
FAX: (905) 522-8804
Email: szechtma@mcmaster.ca

ABSTRACT

Chronic treatment of rats with the D2/D3 dopamine agonist quinpirole induces compulsive checking (proposed as animal model of obsessive-compulsive disorder; OCD) and locomotor sensitization. The mechanisms by which chronic quinpirole produces those behavioral transformations are not known. Here we examined whether changes in gut microbiota play a role in these behavioral phenomena by monitoring the development of compulsive checking and locomotor sensitization at the same time as measuring the response of gut microbiota to chronic quinpirole injections. Two groups of rats received 9 injections of saline (n=16) or guinpirole (n=15; 0.25 mg/kg), at weekly intervals for the first 5 weeks and then 2 injections per week until end of treatment. After each injection, rats were placed on a large open field for 55 min and their behavior was video recorded for subsequent analysis. Fecal matter was collected after each trial and frozen for bacterial community profiling of the 16S rRNA gene using paired end reads of the V3 region. Results indicated that the induction of locomotor sensitization and compulsive checking was accompanied by changes in several communities of bacteria belonging to the order Clostridiales (class Clostridia, phylum Firmicutes), and predominantly in Lachnospiraceae and Ruminococcaceae families of bacteria. It is suggested that changes in these microbes may serve to support the energy utilization requirements of compulsive checking and OCD.

KEYWORDS

Compulsive checking behavior; locomotor sensitization; quinpirole; gut microbiota; Lachnospiraceae; energy metabolism; hyperactivity; security motivation system; animal model; obsessive-compulsive disorder;

INTRODUCTION

An acute injection of the D2/D3 dopamine agonist quinpirole has a marked effect on the behavior of rats exploring a large open field: explored space becomes constricted such that the routes of travel are confined to only a limited portion of the environment, unlike the trajectories of locomotion of saline-treated animals that are dispersed widely throughout the arena and cover the entire perimeter boundary of the open field (Eilam et al, 1989b; Eilam et al, 1991). Also, an acute injection of quinpirole may change somewhat the amount of locomotion (Eilam et al, 1989b; Eilam and Szechtman, 1989d; Eilam *et al*, 1992) but with chronic injections of the drug, activity is strikingly elevated: there is a 3 to 8 fold increase in distance traveled after 8 to 10 injections of quinpirole, compared to the acute quinpirole response (Szechtman et al, 1994a; Szechtman et al, 1994c; Einat et al, 1996; Szumlinski et al, 2000; Lomanowska et al, 2004; Culver et al, 2008; Ballester Gonzalez et al, 2015). This augmented response is an instance of behavioral or locomotor "sensitization" - a general phenomenon of enhanced responding to psychostimulant drugs with chronic treatment (Robinson and Becker, 1986; Stewart and Badiani, 1993; Wise and Leeb, 1993). The phenomenon of behavioral sensitization has attracted much research interest because of its potential relevance to mechanisms of various psychiatric disorders such as psychosis, mania, and addiction (Ellinwood, 1968; Ellison, 1979; Post and Contel, 1981; Segal and Schuckit, 1983; Robinson and Berridge, 1993; Antelman et al, 2000; Shaldubina et al, 2002). With respect to behavioral sensitization to quinpirole, it too may be of relevance to a psychiatric disorder, namely, obsessive-compulsive disorder (OCD) (Szechtman et al, 1999; Eilam and Szechtman, 2005; Stuchlik et al, 2016).

The notion that behavioral sensitization to quinpirole may be of relevance to OCD emerged from the findings that the spatial-temporal structure of activity by quinpirole-sensitized rats meets the criteria of compulsive behavior performed by OCD patients (Szechtman *et al*, 1998; Eilam *et al*, 2012). Accordingly, it was proposed that the transformation in behavior induced by chronic quinpirole constitutes an animal model of OCD of use for probing the mechanisms of this disorder and of the symptom of compulsive checking in particular (Man *et al*, 2004; Korff and Harvey, 2006; Westenberg *et al*, 2007; Hoffman, 2011; Albelda and Joel, 2012; Alonso *et al*, 2015; Grados *et al*, 2016).

Much of the animal research on mechanisms of OCD and locomotor sensitization to quinpirole examine central processes. For instance, using the 2-deoxyglucose technique to measure local cerebral glucose utilization in quinpirole-sensitized animals (Carpenter *et al*, 2003; Richards *et al*, 2005), alterations had been found in cortical (the cingulate

cortex-area 1, frontal cortex-area 3, lateral orbital cortex, medial/ventral orbital cortex, and parietal cortex) and subcortical areas (ventral pallidum and nucleus accumbens); more recently, changes in the cortico-striato-thalamico-cortical circuit had been observed by PET neuroimaging in quinpirole-sensitized rats (Servaes *et al*, 2016). Others report in quinpirole-sensitized animals: increased high-affinity states of dopamine D2 receptors (D2^{High}) (Seeman *et al*, 2006; Perreault *et al*, 2007; Culver *et al*, 2008); decreased dopamine levels in the left pre-frontal cortex (Sullivan *et al*, 1998); reduced dopamine and glutamate neurotransmission in the nucleus accumbens (Escobar *et al*, 2015); as well alterations in dopamine-serotonin interaction (Alkhatib *et al*, 2013; Tucci *et al*, 2013; Johnson and Szechtman, 2016). However, it remains to be established which of those findings, if any, are necessary for the pathophysiology of compulsive checking (Szechtman *et al*, 2014).

While a research focus on central mechanisms underlying OCD and behavioral sensitization is a very reasonable strategy, a plausible contribution of peripheral mechanisms should not be discounted, given findings of peripheral immune factors altering behavior (Sakic *et al*, 1997; Kapadia and Sakic, 2011) and the possibility of gutbrain signaling modulating behavioral performance (Sekirov *et al*, 2010; Bercik *et al*, 2011; Collins *et al*, 2013; Bharwani *et al*, 2016; Foster, 2016; Stilling *et al*, 2016; Dinan and Cryan, 2017a). Moreover, there are suggestions for a role of peripheral mechanisms in quinpirole sensitization (Coscina *et al*, 1998; Baladi and France, 2009, 2010) and OCD (Swedo *et al*, 1998; da Rocha *et al*, 2008; Rees, 2014; Turna *et al*, 2016).

In the present study, we investigate the possibility of a role for peripheral mechanisms —and of gut microbiota in particular —in the phenomena of quinpirole-induced locomotor sensitization and compulsive checking. It was expected that if gut microbiota plays a role in these phenomena then during development of locomotor sensitization and compulsive checking a change in bacterial composition should be induced as a function of chronic quinpirole treatment. Results indicate that the induction of locomotor sensitization and compulsive checking was indeed accompanied by changes in gut bacterial composition, predominantly within the taxon Clostridiales (order).

MATERIALS AND METHODS

ANIMALS

A total of 32 experimentally naive Long-Evans male rats (Charles River, St Constant, Quebec, Canada), weighing 260–330 g at the start of testing, entered the study. Animals were housed individually in a climate controlled colony room on a 12 hour light/dark cycle (6 AM lights on, 6 PM lights off). Food and water were freely available. Upon arrival, rats were allowed to habituate to the animal facility for 7 days and were then handled for approximately 2-5 minutes each day for 5 days in the week before start of behavioral testing. Testing occurred during the light phase. Animals were housed and tested as approved by the Animal Research Ethics Board, McMaster University in compliance with the Canadian Council on Animal Care guidelines.

DRUGS

(-)-Quinpirole hydrochloride (Q102; Sigma-Aldrich) was dissolved in 0.9% physiological saline, and administered at a dose of 0.25 mg/kg in a volume of 1 ml/kg through a subcutaneous injection under the nape of the neck. Control animals were similarly injected with 1 ml/kg of 0.9% physiological saline. Maximum effect of quinpirole for locomotor sensitization is observed at a dose of about 0.2–0.5 mg/kg (Szechtman *et al*, 1994b; Szechtman *et al*, 1994c; Szumlinski *et al*, 1997; Perreault *et al*, 2005; Dvorkin *et al*, 2006a); in studies of compulsive checking the typical dose employed is 0.5 mg/kg (Szechtman *et al*, 1998; Zadicario *et al*, 2007; Winter *et al*, 2008; Mundt *et al*, 2009; Dvorkin *et al*, 2010; Ballester Gonzalez *et al*, 2015) but lower doses (0.2-0.25 mg/kg) had been found effective as well (Alkhatib *et al*, 2013; Tucci *et al*, 2014).

APPARATUS

Animals were tested on a large open field (160 x 160 cm and 60 cm high table without walls) that was located in a non-colony room illuminated by usual overhead fluorescent lights, as described previously (Dvorkin *et al*, 2006b; Dvorkin *et al*, 2010). The table was divided virtually into a grid of 25 rectangular places (locales), but no actual lines were marked on the table surface. Four small Plexiglas/glass boxes (approximately 8×8×7.5 cm) were located at the same fixed location on the open field throughout the study: two at corners and two at places near the center of the open field (Szechtman *et al*, 1998). After each rat was tested, the table and objects were wiped clean with a diluted solution of an antibacterial cleaner (Lysol). Behavior on the open field was recorded by a stationary overhead camera interfaced with a computer that stored the video signal as MPEG files for offline analysis. These digitized videos were used to automatically track the trajectories of locomotion in the open field using EthoVision 3.1 (Noldus Information Technology, Netherlands) software (Noldus *et al*, 2001; Spink *et al*, 2001).

GUT MICROBIOTA PROFILING

Gut microbial composition was assessed by sequencing the bacterial 16S rRNA gene collected from fecal pellets deposited by the rat during the open field test. The collected fecal pellets were stored at -80 °C until molecular analysis of microbiota.

-5-

Bacterial DNA extraction was carried as previously described (Whelan et al., 2014). Bacterial community profiling of the 16S rRNA gene was performed using paired end reads of the V3 region. Triplicate amplifications were pooled for 250 nt paired-end MiSeq Illumina sequencing. This approach provides overlapping sequence reads of the V3 region, which can be used for correcting poor quality base calls and increasing sequencing accuracy. Sequence data were processed by an in-house bioinformatics pipeline (Whelan et al, 2014; De Palma et al, 2015) that incorporates quality filtering, sequence trimming and read assembly [Cutadapt (Martin, 2011) and PANDAseq (Masella et al, 2012)]. Bacterial sequences were clustered into de novo operational taxonomic units (OTUs) with the AbundantOTU+ algorithm (Ye, 2011). Taxonomy was assigned with the Ribosomal Database Project (RDP) Classifier in QIIME (Caporaso et al, 2010) and the Greengenes training set (February 2011 release). OTUs rarefied to 43,345 were used in statistical analysis; singletons and non-bacterial sequences were excluded. DNA extraction and 16S rRNA gene sequencing were carried out in the McMaster Genome Center (McMaster University). Raw sequence reads have been deposited in the NCBI Short Read Archive under BioProject xxxxxxxxxx.

BEHAVIOURAL DATA ANALYSIS

EthoVision 3.1 software was used to extract the time series of x, y coordinates of the rat from digitized video recordings (Dvorkin *et al*, 2006b; Dvorkin *et al*, 2010). To remove noise, digitized tracking data were pre-processed (by applying appropriate filters to smooth the x, y coordinates) (Hen et al, 2004), and the obtained coordinates were divided into episodes of forward locomotion (called progression) and episodes of small movements or immobility (called lingering), as described previously (Golani et al, 1993; Drai et al, 2000; Drai and Golani, 2001). The coordinate system was mapped onto the 25 open field locales (places) (Szechtman et al, 1998), and the frequency of visits and duration of stops in each locale were computed (the terms 'visit' and 'stop' are equivalent and are used interchangeably). Checking behavior was defined with reference to the most visited locale (labeled 'key place' or 'key locale'; these terms are equivalent), which in most instances is also the locale with the longest total duration of stops (Eilam and Golani, 1989a; Szechtman *et al*, 1998). A visit to the key place is also referred to as a 'check' or 'checking', and the following set of four measures of checking behavior were computed. (1) Frequency of checking: total number of visits to the key locale. (2) Length of check: total duration of stay at the key locale divided by the frequency of visits there; this measure is also an indirect index of ritual-like behavior as the appearance of motor rituals in quinpirole-treated rats is associated with a very short duration of stay in the key locale (Szechtman *et al*, 1998; Ben Pazi *et al*, 2001). (3) Recurrence time of checking: mean duration of return times to the key locale ('return

time' is the interval from departure to next arrival at the locale). (4) Stops before returning to check: mean number of places visited between returns to the key locale. Compulsive checking behavior is identified by the presence of a significant difference between quinpirole- and saline-treated rats – all four measures need to differ from controls for the claim of 'compulsive' checking (Szechtman *et al*, 1998), and hence the set of these four measures is termed 'criteria measures' for compulsive checking.

In addition to the above criteria measures, we also evaluate "time to next checking bout" (Dvorkin *et al*, 2006b). This measure is greatly reduced in quinpirole-sensitized rats and has been proposed to index the third constitutive component of compulsive checking behavior—"satiety" or rest after checking (Dvorkin *et al*, 2010). The computation of checking bouts is detailed in Dvorkin *et al*. (2006b) and a modification in Tucci *et al*. (2013).

Total distance traveled was calculated as the sum of distances moved in progression segments and lingering episodes. For the spatial distribution of routes of travel, two indices were used: path stereotypy ratio and area of 2 standard deviational ellipse (2SDE), computed according to the method detailed elsewhere (Dvorkin *et al*, 2006a). The first index, path stereotypy ratio, reflects the relative frequency of repetitions of travel along the same paths while the second index is a measure of the extent of the area covered by the trajectories of locomotion.

DESIGN AND PROCEDURE

Two groups of rats were tested: the experimental group (N=15) received injections of quinpirole (QNP), while the control group (N=16) received a similar regimen of saline injections. Animals were assigned to treatment groups at random. Originally the two groups had an equal number of subjects but one rat from the quinpirole group was removed from the experiment early on due to concerns with its health.

The typical regimen of quinpirole injections in studies of locomotor sensitization or compulsive checking are twice weekly injections (Szechtman *et al*, 1998; Dvorkin *et al*, 2006b). The behavioral effects of chronic treatment with quinpirole reach a plateau at approximately 8 injections administered 2–8 days apart (Szechtman *et al*, 1994b; Szechtman *et al*, 1994c; Perreault *et al*, 2005; Dvorkin *et al*, 2006b). The regimen of quinpirole injections chosen for the present study fell within these parameters but the typical regular schedule of drug administrations was modified to accommodate the requirements of a second objective for which these rats were being tested. Specifically, the experiment served also to evaluate gene expression changes as a function of chronic treatment with quinpirole, an objective that required the sampling of blood. Because a

two week interval between samplings was required, rats were tested on the open field once a week for the first 5 quinpirole treatments and twice per week for injections 6 to 9. Blood was sampled from the tail vein on the day following injections 1, 3, 5 and 9 (the gene expression findings will not be discussed here). Fecal pellets were collected after each test but were analyzed only for injections 1, 5 and 9 as these three time points were expected to provide a good snapshot of the start, middle and end of the sensitization process.

For all tests the same procedure was followed: Animals were weighed, transported in their home cage to an adjoining non-colony experimental testing room, and administered the appropriate injection. Immediately afterwards, the rat was placed into the open field for 55 min and its behavior videotaped for offline analysis. Each rat was run on the same assigned days of the week, at approximately the same time of day, and by the same experimenter for 9 trials. Each experimenter was assigned a balanced number of rats from every experimental group.

STATISTICAL ANALYSIS

To assess the development of checking behavior and locomotor sensitization across injections 1 to 9, regression estimates for each dependent variable were computed for each rat. The obtained individual slopes and intercepts were then analyzed statistically using a Group (saline *vs.* quinpirole) 1-way ANOVA. To correct for skew in the data, the variables *length of check* and *time to next checking bout*, were log transformed for statistical analysis. QIIME software was used for group comparison of OTUs using the Kruskal Wallis (KW) test. The OTU data identified as significant by KW were imported into SPSS (IBM SPSS Statistics 23) and analyzed with a 2x3 repeated measures ANOVA, where the Drug factor had two levels (saline vs quinpirole) and the repeated measures Injection factor had 3 levels (injection 1, injection 5 and injection 9).

RESULTS

INDUCTION OF COMPULSIVE CHECKING AND LOCOMOTOR SENSITIZATION

To examine whether changes in gut microbiota accompany the behavioral response to quinpirole, we first establish that in the present experiment the current protocol of quinpirole injections was effective in inducing the expected development of compulsive checking as well as locomotor sensitization and alteration in the spatial distribution of locomotion.

Figure 1 (*left* panel) displays the criteria measures defining compulsive checking *frequency of checking, length of check, recurrence time of checking,* and *stops before returning to check.* The graph shows the profile of these measures during injections 1 to 9 for the saline (*open circles*) and quinpirole-injected rats (*open squares*). Compulsive checking is expected after 8 to 10 injections of quinpirole; evidence for compulsive checking requires the presence of a significant difference between the quinpirole- and saline-treated rats on all 4 criteria measures (Szechtman *et al*, 1998; Dvorkin *et al*, 2006b; Dvorkin *et al*, 2010; Szechtman *et al*, 2017). As evaluated on injection 9 and indicated by the light gray rectangles in the figure, the quinpirole and saline groups were as expected significantly different from each other on all 4 criteria measures (t-tests, $p\leq.003$). Hence, this study regimen of quinpirole injections was effective in inducing compulsive checking.

Figure 1 (*right* panel) shows another variable—*duration of rest* after a bout of checking that has been suggested to constitute a component of compulsive checking and which characteristically is short in quinpirole-treated rats (Dvorkin *et al*, 2006b; Dvorkin *et al*, 2010). In the present study, as expected, and as shown by the light gray rectangle in the figure, the duration of rest on injection 9 was significantly shorter in the quinpirole-treated rats compared to the saline controls (*t*-test, t(9) = 2.028, p = 0.037, 1-tail).

The time course of development of compulsive checking can be assessed by examining the regression line for each criterion measure across injections. Prior analyses show that chronic treatment with quinpirole produces two distinct effects on these regression lines (Tucci et al, 2014; Ballester Gonzalez et al, 2015): For frequency of checking and *length of check,* repeated injections of quinpirole alter the slope but not the intercept of the regression line, compared to the saline group. For recurrence time of checking and stops before returning to check, quinpirole produces a shift in the intercept of the regression line without effect on the slope, compared to the saline group. The frequency of checking and length of check are variables that index the vigor in the motor performance of checking while recurrence time of checking and stops before returning to check are variables related to the focus on the task of checking (Dvorkin et al, 2010). Accordingly, the findings of altered slope but not intercept for measures of vigor indicate that only the vigor of checking sensitizes with repeated injections of quinpirole. In contrast, the findings of altered intercept but not slope for measures of focus indicate that guinpirole increases focus acutely, and this acute effect persists unabated throughout the course of chronic quinpirole treatment (Dvorkin et al, 2006b; Tucci et al, 2014; Ballester Gonzalez et al, 2015).

Figure 1 shows the calculated regression lines for each measure of compulsive checking for the saline- and quinpirole-injected groups in the present study, indicated by the *solid thin* line and the *solid thick* line, respectively. Parameters of these regression lines as well as the statistical analysis of these parameters are shown in Table 1. As can be seen, the regimen of quinpirole injections used in the present study yielded the same pattern of results as noted above, except that the intercepts of the regression lines for *frequency of checking* were also significantly different between the saline and quinpirole groups (Table 1). Nevertheless, it is evident that the quinpirole treatment used in the present study produced the expected profile of changes across injections during development of compulsive checking.

LOCOMOTOR SENSITIZATION AND ROUTES OF TRAVEL

Figure 2a shows the trajectories of locomotion shown by a rat injected with saline (top row) and a rat injected with quinpirole (bottom row) during the course of 9 treatments. The chosen rats are nearest their group mean of distance travelled in the experiment (saline mean \pm SEM = 43.0 \pm 6.6 m; guinpirole mean \pm SEM = 236.2 \pm 38.9 m) and illustrate the key features of changes across injections in their respective groups. Quantitative analyses for these routes of travel are presented in Figure 2bcd and involve variables shown previously to exhibit a specific profile which accompanies guinpiroleinduced compulsive checking (Eilam et al, 1989c; Szechtman et al, 1994c; Dvorkin et al, 2006a; Dvorkin et al, 2006b; Dvorkin et al, 2010). In particular, it was shown previously that routes of travel by quinpirole rats with compulsive checking are characterized by: (i) elevated amount of locomotion, as measured by distance travelled; (ii) shrinkage of explored space, as measured by 2 standard deviational ellipse (2SDE) and, (iii) restriction of locomotion to repeated travel along a few routes only, as measured by path stereotypy. Such changes in each variable are also evident in Figure 2a by a visual comparison of routes of travel on injection 9 under saline versus quinpirole. More locomotion (and hence a higher value for distance travelled) is evident by greater density of trajectories in the quinpirole rat compared to the saline control. Shrinkage of explored space in the quinpirole rat (and hence a lower value for 2SDE) is evident by paths being distributed over a relatively narrow area of the open field versus paths of the saline rat being dispersed over the entire environment and edges of the perimeter boundary. Finally, more repetitions of travel along a few routes (and hence a higher value for path stereotypy) is evident by few yet thick trajectories in the quinpirole rat compared to many and thin trajectories of locomotion in the saline rat. Statistical comparisons of these measures on injection 9 for saline and guinpirole rats showed the expected significant group differences (t-tests, p<.001, light gray rectangles in Figure 2bcd), indicating the efficacy of the quinpirole treatment used in the present study.

The regression lines in Figure 2bcd show the time course of change in these measures during the course of treatment; the parameters of the regression lines are presented in Table 1. Comparison of the parameters from the present study to prior findings (Ballester Gonzalez *et al*, 2015) suggests that while the present regimen of quinpirole injections was effective in producing the salient features on routes of travel (locomotor sensitization, shrinkage of explored space and increase in path stereotypy), the intensity of these effects was smaller compared to findings in Ballester Gonzalez *et al* (2015), especially in terms of a smaller increase in distance travelled and in path stereotypy across injections.

EFFECTS OF QUINPIROLE ON GUT MICROBIOTA

Table 2 presents the list of 25 gut bacteria clusters identified through statistical analyses as likely altered because of chronic treatment with quinpirole. These clusters passed the following statistical analyses to emerge as potentially related to repeated injections of quinpirole:

First, profiling of bacterial composition produced 4313 operational taxonomic units (OTUs) appropriate for statistical analyses by Kruskal-Wallis (KW). The KW non-parametric 1-way analysis of variance treated the data as emanating from 6 independent groups, formed from the combination of two treatments (saline vs quinpirole) and 3 injections (injection 1, injection 5 and injection 9); OTUs with non-zero values in at least 20% of samples entered the statistical analysis. The KW analysis yielded 232 OTUs which showed a significant main effect (p<.05).

Second, the statistically significant OTUs from KW analysis were re-analyzed using a 2x3 repeated measures ANOVA, where Saline vs Quinpirole was the between-subjects Drug factor and Injections 1, 5 and 9 was the within-subjects repeated measures Injection factor. This statistical analysis yielded a total of 219 OTUs with a significant main or interaction effects: the main effect of Drug was found in 50 OTUs, the main effect of Injection in 178 OTUs, and a significant Drug by Injection interaction for 25 OTUs. These 25 OTUs are shown in Table 2 as potentially related to chronic injections of quinpirole because no drug effect is expected 55 min after injection 1 (when the first fecal pellets were collected) but to emerge over days as a function of quinpirole injections, yielding an interaction effect.

As is evident from Table 2, 22 of the 25 significant OTUs are from the phylum Firmicutes. The three remaining OTUs are one each from the phyla Deferribacteres, Proteobacteria, and Tenericutes.

All of the 22 OTUs from the phylum Firmicutes belong to the class Clostridia, order Clostridiales. At a still finer taxonomic level, the highest frequency of OTUs (9 in total) is in the family *Lachnospiraceae*, followed by 7 OTUs in the family *Ruminococcaceae* (Table 2). Two examples of the change in OTUs from *Lachnospiraceae* are displayed graphically in Figure 3.

Although all the above OTUs are statistically significant from our analysis, it is evident that many of the OTUs have low rarefied counts (Table 2). These OTUs may represent low abundant taxa, and as such they are subject to sampling noise in rarefication process.

DISCUSSION

In the present study the changes in behavior to repeated injections of quinpirole, namely, the development of compulsive checking and of locomotor sensitization, were monitored at the same time as was the response of gut microbiota to these drug injections. Behavior and microbiota were monitored concurrently as it was expected that if they are linked then evidence of an association should be present. Indeed, the present findings provide evidence consistent with the hypothesis of a relationship between changes in gut microbiota and development of locomotor sensitization or compulsive checking or both. Results showed that changes in behavior that occur after several injections of quinpirole were temporally accompanied by changes in several clusters of gut bacteria. Specifically, after some injections of quinpirole significant responses were found in 25 OTUs, with the vast majority of OTUs (22) belonging to the order Clostridiales and the class Clostridia in the phylum Firmicutes. At a finer level of taxonomy, 9 OTUs were in the *Lachnospiraceae* family and 7 OTUs were in the *Ruminococcaceae* family of bacteria.

Of possible relevance to the present findings, an effect on these gut microbiota has been reported in the following two studies. In one study, Ning *et al* (2017) report that in rats treated repeatedly with the indirect dopamine agonist methamphetamine and tested for conditioned place preference, there was an associated alteration in the intestinal microbiota, and amongst those changes there was an increase in OTUs from the family *Ruminococcaceae*. In another recent study of gut microbiota, Hill-Burns *et al* (2017) confirmed the findings of a prior study (Keshavarzian *et al*, 2015) of reduced levels of *Lachnospiraceae* in patients with Parkinson Disease (PD). Together with our results, these findings point towards a likely relationship between dopamine activity and effect on those particular colonies of gut microbiota.

One vital role of gut microbiota is to metabolize resistant starches and dietary fibers through fermentation and decomposition, yielding as end products short chain fatty acids (SCFAs) which include acetate, propionate and butyrate (den Besten *et al*, 2013; Ohira *et al*, 2017). Of the two most abundant phyla in the intestine, the Bacteroides phylum has as its metabolic end product mainly acetate and propionate and the Firmicutes phylum produces largely butyrate (den Besten *et al*, 2013). *Lachnospiraceae* and *Ruminococcaceae* are the most abundant Firmicutes families in gut environments (Biddle *et al*, 2013; Meehan and Beiko, 2014). Recently, much interest has been focused on the butyrate producing bacteria, though *Lachnospiraceae* and *Ruminococcaceae* are not the only families to do this and not all members have butyrate-producing pathways (Biddle *et al*, 2013; Vital *et al*, 2014). Butyrate (also known as butanoic acid, butanoate, and butyric acid) is a short-chain fatty acid that provides energy for other microbes and host cells, promotes energy expenditure, as well as facilitating fatty acid oxidation and lipolysis (Gao *et al*, 2009; Sekirov *et al*, 2010; Williams *et al*, 2011; den Besten *et al*, 2013; Meehan *et al*, 2016; Stilling *et al*, 2016).

While the present study provides evidence consistent with an association between the behavioral and gut microbiota phenomena, it does not address the question of the cause-effect direction underlying the observed association nor the putative mechanisms. The change in bacterial composition could be a direct effect of the drug on gut microbiota, driving the change in behavior. Alternatively, the change in bacterial composition could be contributing to the change in behavior but itself be a consequence of the injection effect on host physiology and/or nervous system. It is also plausible that the change in bacterial composition and the change in behavior are two totally independent and unrelated effects of the drug treatment. As a correlational study the present results do not provide evidence addressing these or any variation of these possibilities. Nevertheless, we can offer some suggestions that can provide a useful framework to generate hypotheses for further studies. Below, we first consider two contrasting perspectives to frame the connecting relationship between gut microbiota and behavior and then use one of them to speculate on a plausible mechanism underlying the observed association between gut microbiota and development of compulsive checking and locomotor sensitization.

TWO PERSPECTIVES

There is a rapidly expanding literature reporting on studies that show specific changes in gut microbiota and perturbations in particular behaviors, and vice-versa, raising the concept of an active and bidirectional microbiota-gut-brain axis (Collins *et al*, 2012; De Palma *et al*, 2014; Foster, 2016; Dinan and Cryan, 2017b; Zhu *et al*, 2017). Below, we outline two possible but polar models linking microbiota and behavior: one model in which gut microbiota are sufficient to produce a change in behavior and another one in which microbiota are neither necessary nor sufficient for the change in behavior.

MODEL OF MICROBIOTA STIMULATING BEHAVIOR

One way to conceptualize an observed association between gut microbiota and behavior is the perspective that gut microbes drive behavior. This perspective holds that there is a direct pathway from some particular gut microbiota to stimulation of specific neural circuits mediating unique behavioral actions. An extreme example of such a schema is illustrated by recent studies on manipulation of host biology and behavior through infection by the brain parasite *Toxoplasma gondii (T. gondii)* (Torrey et al, 2007; Kaushik et al, 2012; Flegr, 2013; Evans et al, 2014). T. gondii-infected rats and mice lose their natural avoidance of predator odor and open spaces, resulting in increased feline predation of the infected rodents and the ensuing passage of the parasite into the feline host for the next stage of its life cycle (Kaushik et al, 2012). The mechanism by which the parasite induces the particular change in rodent behavior involves cyst localization to specific neuroanatomical regions and interaction thein with the behaviorally functional neural circuit (Prandovszky et al, 2011; Kaushik et al, 2012; Evans et al, 2014). Because T. gondii enters the host through the intestinal tract, it affects behavior through its initial effects on the intestinal tract (Severance et al, 2016). A conceptually similar infectious model had been proposed for producing OCD (Rotge et al, 2010).

A growing body of literature is showing that without acquisition of infection, nonpathogenic alteration in the composition of the commensal bacteria can also change behavior. A particularly dramatic illustration of this relationship is a study showing that colonization of germ-free BALB/c mice with microbiota from two different mice strains produced strain-specific behavioral phenotypes in the recipient animals (Bercik *et al*, 2011). Although the mechanisms linking commensal bacteria and behavior are yet unidentified, there is evidence for multiple ways by which gut microbiota could activate brain circuits mediating behavior: Considering that microbiota elaborate a wide range of appropriate signaling molecules (monoamines, SCFAs and hormones) and have epitopes recognizable by both intestinal epithelial and mucosal immune cells, it follows that gut microbiota have access to neuronal (vagus, enteric nervous system), endocrine, as well as immune channels for communication with the brain (Roshchina, 2010; Sekirov *et al*, 2010; Collins *et al*, 2012; Erny *et al*, 2015; Neuman *et al*, 2015; Stilling *et al*, 2016; Woo and Alenghat, 2017).

In all, according to the "microbiota stimulating behavior" model, an observed association between gut microbiota and behavioral phenotype indicates a relatively direct effect of the specific microbes on brain-specific neural circuits driving the behavioral phenotype.

MODEL OF INFRASTRUCTURAL SUPPORT

In contrast to the above model of behavioral activation by a relatively direct pathway from the gut to the brain, a model of "infrastructural support" does not draw a causal pathway from the change in microbiota to an associated change in behavior. Rather, it considers that the association reflects only some supportive role played by the microbiota in the performance of the behavior and the alteration in microbiota is neither necessary nor sufficient to drive the observed behavioral change. Although this model holds that the microbiota change is not causative of the change in behavior, it leaves open that the two phenomena can be relatively strongly coupled and that the microbiota change is important for the change in behavioral phenotype, as elaborated below.

The infrastructure model is built on the observation that normally gut microbiota have a symbiotic association with their host and play a prominent role in nutrition, immune regulation and maintenance of barrier function (Jandhyala *et al*, 2015). As such, rather than drive behavior directly, the role of alterations in gut microbiota may be to provide the infrastructural support needed for the organism to work and function in an adaptive fashion as demanded by circumstances. For instance, when the type of diet consumed changes then the composition of gut commensals changes accordingly to process the new nutrients (Turnbaugh *et al*, 2009; Wu *et al*, 2011; David *et al*, 2014; Wang *et al*, 2014).

Accordingly, the perspective of the infrastructural support model holds that an observed association between gut microbiota and behavioral phenotype indicates the presence of an accommodation of gut microbiota for supporting the physiological demands of the behavioral phenotype. The two phenomena are fully independent, but can become coupled in time.

PRIMING OF ENERGY SYSTEMS FOR RAPID DEPLOYMENT

In the present study the observed association between microbiota and behavior was produced by chronic quinpirole experience. Our hypothesis for this finding is that it reflects the infrastructure role of the altered microbiota in energy metabolism facilitating the behavioral phenotype. The rationale for this hypothesis is as follows.

The enhanced motor performance of quinpirole-sensitized rats raised the suggestion (Szechtman *et al*, 1994c) that the dopamine agonist acts on central energy control mechanisms that enable motor vigor (Vissing *et al*, 1989a; Vissing *et al*, 1989b; Scheurink and Steffens, 1990; Schwartz *et al*, 1992; Szechtman *et al*, 1994c), consistent with exacerbated "feelings of energy" often experienced with psychostimulant drugs (Smith and Beecher, 1960; Laties and Weiss, 1981; Post and Contel, 1983). Measurements of energy metabolism in quinpirole sensitized rats yielded findings consistent with an enhanced sense of energy in that in quinpirole- sensitized rats, energy metabolism (as measured by VCO₂/VO₂ respiratory quotient) is shifted towards utilization of a more energy-rich fuel, free fatty acid (FFA).

The present findings that most of the quinpirole-related changes in gut microbiota occurred in *Lachnospiraceae* and *Ruminococcaceae* bacteria may constitute in part the mechanism for the shift noted above towards utilization of FFA by quinpirole-sensitized rats. As noted, microbes from these families produce butyrate that provides energy for other microbes and host cells, promotes energy expenditure, as well as facilitating fatty acid oxidation and lipolysis (Gao *et al*, 2009; Williams *et al*, 2011; Meehan *et al*, 2014; Hong *et al*, 2016). Hence, one of the functional effects of quinpirole-induced altered microbiota may be to promote the shift towards FFA utilization observed in quinpirole-sensitized rats (Coscina *et al*, 1998).

If the change in microbiota does indeed contribute to the above shift in energy utilization with quinpirole then in addition to enabling sensitized locomotion, the microbiota plays a role also in the performance of compulsive checking and hence by implication from the animal model, in OCD. This suggestion follows from the security motivation theory of OCD (Szechtman and Woody, 2004; Woody and Szechtman, 2005) and in particular from a consideration of the physiological processes fueling the security motivation system (SMS). As elaborated elsewhere (Woody and Szechtman, 2011), the physiology of an activated SMS primes energy resources for rapid mobilization should maximal exertion becomes necessary if a real threat is encountered, and the "fight or flight" response is engaged (Cannon, 1927). An activated SMS primes, but does not mobilize the energy resources, because motor activity engendered by "security motivation – for example, checking for predators – is not physically strenuous and hence not highly demanding of energy resources" (Woody *et al*, 2011). Nevertheless the

motor actions of security motivation (precautionary and probing behaviors) do require an elevation in energy, an energy expenditure demand that can be met by a greater supply and utilization of FFA. Accordingly, the observed changes in *Lachnospiraceae* and *Ruminococcaceae* bacteria may serve to support the energy needs of compulsive checking and OCD.

COMPETING INTERESTS

The authors declare no competing interests.

ACKNOWLEDGEMENTS

This study was supported by funds from an operating grant to HS from the Ontario Mental Health Foundation (OMHF).

References

Albelda N, Joel D (2012). Current animal models of obsessive compulsive disorder: an update. *Neuroscience* **211**(0): 83-106.

Alkhatib AH, Dvorkin-Gheva A, Szechtman H (2013). Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit. *Behav Pharmacol* **24**(1): 65-73.

Alonso P, Lopez-Sola C, Real E, Segalas C, Menchon JM (2015). Animal models of obsessive-compulsive disorder: utility and limitations. *Neuropsychiatr Dis Treat* **11**: 1939-1955.

Antelman SM, Levine J, Gershon S (2000). Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. *Mol Psychiatry* **5**(4): 350-356.

Baladi MG, France CP (2009). High fat diet and food restriction differentially modify the behavioral effects of quinpirole and raclopride in rats. *Eur J Pharmacol* **610**(1-3): 55-60.

Baladi MG, France CP (2010). Eating high-fat chow increases the sensitivity of rats to quinpirole-induced discriminative stimulus effects and yawning. *Behav Pharmacol* **21**(7): 615-620.

Ballester Gonzalez J, Dvorkin-Gheva A, Silva C, Foster JA, Szechtman H (2015). Nucleus accumbens core and pathogenesis of compulsive checking. *Behav Pharmacol* **26**(1-2): 200-216.

Ben Pazi A, Szechtman H, Eilam D (2001). The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. *Behav Neurosci* **115**(6): 1301-1317.

Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, *et al* (2011). The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. *Gastroenterology* **141**(2): 599-609, 609 e591-593.

Bharwani A, Mian MF, Foster JA, Surette MG, Bienenstock J, Forsythe P (2016). Structural & functional consequences of chronic psychosocial stress on the microbiome & host. *Psychoneuroendocrinology* **63**: 217-227.

Biddle A, Stewart L, Blanchard J, Leschine S (2013). Untangling the Genetic Basis of Fibrolytic Specialization by Lachnospiraceae and Ruminococcaceae in Diverse Gut Communities. *Diversity* **5**(3): 627.

Cannon WB (1927). *Bodily changes in pain, hunger, fear, and rage: an account of recent researches into the function of emotional excitement* D. Appleton and Company: New York and London.

Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, *et al* (2010). QIIME allows analysis of high-throughput community sequencing data. *Nature methods* **7**(5): 335-336.

Carpenter TL, Pazdernik TL, Levant B (2003). Differences in quinpirole-induced local cerebral glucose utilization between naive and sensitized rats. *Brain Res* **964**(2): 295-301.

Collins SM, Kassam Z, Bercik P (2013). The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. *Curr Opin Microbiol* **16**(3): 240-245.

Collins SM, Surette M, Bercik P (2012). The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol* **10**(11): 735-742.

Coscina DV, Currie PJ, Szechtman H (1998). Association of altered whole-body metabolism with locomotor sensitization induced by quinpirole. *Physiol Behav* **63**(5): 755-761.

Culver KE, Szechtman H, Levant B (2008). Altered dopamine D2-like receptor binding in rats with behavioral sensitization to quinpirole: effects of pre-treatment with Ro 41-1049. *Eur J Pharmacol* **592**(1-3): 67-72.

da Rocha FF, Correa H, Teixeira AL (2008). Obsessive-compulsive disorder and immunology: a review. *Prog Neuropsychopharmacol Biol Psychiatry* **32**(5): 1139-1146.

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, *et al* (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature* **505**(7484): 559-563.

De Palma G, Blennerhassett P, Lu J, Deng Y, Park AJ, Green W, *et al* (2015). Microbiota and host determinants of behavioural phenotype in maternally separated mice. *Nature communications* **6**: 7735.

De Palma G, Collins SM, Bercik P, Verdu EF (2014). The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? *J Physiol* **592**(14): 2989-2997.

den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res* **54**(9): 2325-2340.

Dinan TG, Cryan JF (2017a). Gut-brain axis in 2016: Brain-gut-microbiota axis - mood, metabolism and behaviour. *Nature reviews Gastroenterology & hepatology* **14**(2): 69-70.

Dinan TG, Cryan JF (2017b). The Microbiome-Gut-Brain Axis in Health and Disease. *Gastroenterol Clin North Am* **46**(1): 77-89.

Drai D, Benjamini Y, Golani I (2000). Statistical discrimination of natural modes of motion in rat exploratory behavior. *J Neurosci Methods* **96**(2): 119-131.

Drai D, Golani I (2001). SEE: a tool for the visualization and analysis of rodent exploratory behavior. *Neurosci Biobehav Rev* **25**(5): 409-426.

Dvorkin A, Culver KE, Szechtman H (2006a). Differential effects of clorgyline on sensitization to quinpirole in rats tested in small and large environments. *Psychopharmacology (Berl)* **186**(4): 534-543.

Dvorkin A, Perreault ML, Szechtman H (2006b). Development and temporal organization of compulsive checking induced by repeated injections of the dopamine agonist quinpirole in an animal model of obsessive-compulsive disorder. *Behav Brain Res* **169**(2): 303-311.

Dvorkin A, Silva C, McMurran T, Bisnaire L, Foster J, Szechtman H (2010). Features of compulsive checking behavior mediated by nucleus accumbens and orbital frontal cortex. *Eur J Neurosci* **32**(9): 1552-1563.

Eilam D, Clements KV, Szechtman H (1991). Differential effects of D1 and D2 dopamine agonists on stereotyped locomotion in rats. *Behav Brain Res* **45**(2): 117-124.

Eilam D, Golani I (1989a). Home base behavior of rats (Rattus norvegicus) exploring a novel environment. *Behav Brain Res* **34**(3): 199-211.

Eilam D, Golani I, Szechtman H (1989b). D2-agonist quinpirole induces perseveration of routes and hyperactivity but no perseveration of movements. *Brain Res* **490**(2): 255-267.

Eilam D, Golani I, Szechtman H (1989c). D2-agonist quinpirole induces perseveration of routes and hyperactivity but no perseveration of movements. *Brain Res* **490**: 255-267.

Eilam D, Szechtman H (1989d). Biphasic effect of D-2 agonist quinpirole on locomotion and movements. *Eur J Pharmacol* **161**: 151-157.

Eilam D, Szechtman H (2005). Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: An ethologlocal approach to the form of compulsive rituals. *CNS Spectrums* **10**(3): 191-202.

Eilam D, Talangbayan H, Canaran G, Szechtman H (1992). Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors. *Psychopharmacology (Berl)* **106**(4): 447-454.

Eilam D, Zor R, Fineberg N, Hermesh H (2012). Animal behavior as a conceptual framework for the study of obsessive–compulsive disorder (OCD). *Behav Brain Res* **231**(2): 289-296.

Einat H, Einat D, Allan M, Talangbayan H, Tsafnat T, Szechtman H (1996). Associational and nonassociational mechanisms in locomotor sensitization to the dopamine agonist quinpirole. *Psychopharmacology (Berl)* **127**(2): 95-101.

Ellinwood EH, Jr. (1968). Amphetamine psychosis. II. Theoretical implications. *IntJ Neuropsychiatry* **4**(1): 45-54.

Ellison GD (1979). Animal models of psychopathology: studies in naturalistic colony environments. In: Keehn JD (ed). *Psychopathology in animals: Research and clinical implications*. Academic Press: New York, pp 81-101.

Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, *et al* (2015). Host microbiota constantly control maturation and function of microglia in the CNS. *Nat Neurosci* **18**(7): 965-977. Escobar AP, Cornejo FA, Olivares-Costa M, González M, Fuentealba JA, Gysling K, *et al* (2015). Reduced dopamine and glutamate neurotransmission in the nucleus accumbens of quinpirole-sensitized rats hints at inhibitory D2 autoreceptor function. *J Neurochem*: n/a-n/a.

Evans AK, Strassmann PS, Lee IP, Sapolsky RM (2014). Patterns of Toxoplasma gondii cyst distribution in the forebrain associate with individual variation in predator odor avoidance and anxiety-related behavior in male Long-Evans rats. *Brain Behav Immun* **37**: 122-133.

Flegr J (2013). Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. *The Journal of experimental biology* **216**(Pt 1): 127-133.

Foster JA (2016). Gut Microbiome and Behavior: Focus on Neuroimmune Interactions. *Int Rev Neurobiol* **131**: 49-65.

Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, *et al* (2009). Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes* **58**(7): 1509-1517.

Golani I, Benjamini Y, Eilam D (1993). Stopping behavior: constraints on exploration in rats (Rattus norvegicus). *Behav Brain Res* **53**(1-2): 21-33.

Grados M, Prazak M, Saif A, Halls A (2016). A review of animal models of obsessivecompulsive disorder: a focus on developmental, immune, endocrine and behavioral models. *Expert Opinion on Drug Discovery* **11**(1): 27-43.

Hen I, Sakov A, Kafkafi N, Golani I, Benjamini Y (2004). The dynamics of spatial behavior: how can robust smoothing techniques help? *J Neurosci Methods* **133**(1-2): 161-172.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, *et al* (2017). Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. *Mov Disord* **32**(5): 739-749.

Hoffman KL (2011). Animal models of obsessive compulsive disorder: recent findings and future directions. *Expert Opinion on Drug Discovery* **6**(7): 725-737.

Hong J, Jia Y, Pan S, Jia L, Li H, Han Z, *et al* (2016). Butyrate alleviates high fat dietinduced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice. *Oncotarget* **7**(35): 56071-56082.

Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D (2015). Role of the normal gut microbiota. *World J Gastroenterol* **21**(29): 8787-8803.

Johnson EF, Szechtman H (2016). A dose-response study of separate and combined effects of the serotonin agonist 8-OH-DPAT and the dopamine agonist quinpirole on locomotor sensitization, cross-sensitization, and conditioned activity. *Behav Pharmacol* **27**(5): 439-450.

Kapadia M, Sakic B (2011). Autoimmune and inflammatory mechanisms of CNS damage. *Prog Neurobiol* **95**(3): 301-333.

Kaushik M, Lamberton PH, Webster JP (2012). The role of parasites and pathogens in influencing generalised anxiety and predation-related fear in the mammalian central nervous system. *Horm Behav* **62**(3): 191-201.

Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, *et al* (2015). Colonic bacterial composition in Parkinson's disease. *Mov Disord* **30**(10): 1351-1360.

Korff S, Harvey BH (2006). Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. *Psychiatr Clin North Am* **29**(2): 371-390.

Laties VG, Weiss B (1981). The amphetamine margin in sports. *Fed Proc* **40**(12): 2689-2692.

Lomanowska A, Gormley S, Szechtman H (2004). Presynaptic stimulation and development of locomotor sensitization to the dopamine agonist quinpirole. *Pharmacology, biochemistry, and behavior* **77**(3): 617-622.

Man J, Hudson AL, Ashton D, Nutt DJ (2004). Animal models for obsessive-compulsive disorder. *Curr Neuropharmacol* **2**(2): 169-181.

Martin M (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnetjournal* **17**(1): 10-12.

Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD (2012). PANDAseq: paired-end assembler for illumina sequences. *BMC Bioinformatics* **13**: 31.

Meehan CJ, Beiko RG (2014). A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. *Genome Biol Evol* **6**(3): 703-713.

Mundt A, Klein J, Joel D, Heinz A, Djodari-Irani A, Harnack D, *et al* (2009). High-frequency stimulation of the nucleus accumbens core and shell reduces quinpirole-induced compulsive checking in rats. *Eur J Neurosci* **29**(12): 2401-2412.

Neuman H, Debelius JW, Knight R, Koren O (2015). Microbial endocrinology: the interplay between the microbiota and the endocrine system. *FEMS Microbiol Rev* **39**(4): 509-521.

Ning T, Gong X, Xie L, Ma B (2017). Gut Microbiota Analysis in Rats with Methamphetamine-Induced Conditioned Place Preference. *Front Microbiol* **8**: 1620.

Noldus LP, Spink AJ, Tegelenbosch RA (2001). EthoVision: a versatile video tracking system for automation of behavioral experiments. *BehavResMethods InstrumComput* **33**(3): 398-414.

Ohira H, Tsutsui W, Fujioka Y (2017). Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for Inflammation and Atherosclerosis? *Journal of atherosclerosis and thrombosis* **24**(7): 660-672.

Perreault ML, Graham D, Bisnaire L, Simms J, Hayton S, Szechtman H (2005). Kappa-Opioid Agonist U69593 Potentiates Locomotor Sensitization to the D2/D3 Agonist Quinpirole: Pre- and Postsynaptic Mechanisms. *Neuropsychopharmacology* **31**(9): 1967-1981.

Perreault ML, Seeman P, Szechtman H (2007). Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). *Behav Neurosci* **121**(5): 976-991.

Post RM, Contel NR (1981). Cocaine-induced behavioral sensitization: A model for recurrent manic illness. In: Perris C, Struwe G, Jansson B (eds). *Biological psychiatry*. Elsevier/North-Holland Biomedical Press: Amsterdam, pp 746-749.

Post RM, Contel NR (1983). Human and animal studies of cocaine: implications for development of behavioral pathology. In: Creese I (ed). *Stimulants: neurochemical, behavioral and clinical perspectives*. Raven Press: New York, pp 169-203.

Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA (2011). The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. *PLoS One* **6**(9): e23866.

Rees JC (2014). Obsessive-compulsive disorder and gut microbiota dysregulation. *Med Hypotheses* **82**(2): 163-166.

Richards TL, Pazdernik TL, Levant B (2005). Altered quinpirole-induced local cerebral glucose utilization in anterior cortical regions in rats after sensitization to quinpirole. *Brain Res* **1042**(1): 53-61.

Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. *Brain Res* **396**(2): 157-198.

Robinson TE, Berridge KC (1993). The neural basis of drug craving: An incentivesensitization theory of addiction. *Brain Res Rev* **18**(3): 247-291.

Roshchina VV (2010). Evolutionary Considerations of Neurotransmitters in Microbial, Plant, and Animal Cells. In: Lyte M, Freestone PPE (eds). *Microbial Endocrinology: Interkingdom Signaling in Infectious Disease and Health*. Springer New York: New York, NY, pp 17-52.

Rotge JY, Aouizerate B, Tignol J, Bioulac B, Burbaud P, Guehl D (2010). The glutamatebased genetic immune hypothesis in obsessive-compulsive disorder. An integrative approach from genes to symptoms. *Neuroscience* **165**(2): 408-417.

Sakic B, Szechtman H, Denburg JA (1997). Neurobehavioral alterations in autoimmune mice. *Neurosci Biobehav Rev* **21**(3): 327-340.

Scheurink AJ, Steffens AB (1990). Central and peripheral control of sympathoadrenal activity and energy metabolism in rats. *Physiol Behav* **48**(6): 909-920.

Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D, Jr. (1992). Insulin in the brain: a hormonal regulator of energy balance. *Endocr Rev* **13**(3): 387-414.

Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al (2006). Psychosis pathways converge via D2high dopamine receptors. *Synapse* **60**(4): 319-346.

Segal DS, Schuckit MA (1983). Animal models of stimulant-induced psychosis. In: Creese I (ed). *Stimulants: Neurochemical, Behavioral and Clinical Perspectives*. Raven Press: New York, pp 131-167.

Sekirov I, Russell SL, Antunes LC, Finlay BB (2010). Gut microbiota in health and disease. *Physiol Rev* **90**(3): 859-904.

Servaes S, Glorie D, Verhaeghe J, wyffels L, Stroobants S, Staelens S (2016). [18F]-FDG PET neuroimaging in rats with quinpirole-induced checking behavior as a model for obsessive compulsive disorder. *Psychiatry Research: Neuroimaging* **257**: 31-38.

Severance EG, Xiao J, Jones-Brando L, Sabunciyan S, Li Y, Pletnikov M, *et al* (2016). Toxoplasma gondii-A Gastrointestinal Pathogen Associated with Human Brain Diseases. *Int Rev Neurobiol* **131**: 143-163.

Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. *J Neural Transm* **109**(3): 433-440.

Smith GM, Beecher HK (1960). Amphetamine, secobarbital, and athletic performance. II. Subjective evaluations of performance, mood states, and physical states. *J Am Med Assoc* **172**: 1502-1514.

Spink AJ, Tegelenbosch RA, Buma MO, Noldus LP (2001). The EthoVision video tracking system--a tool for behavioral phenotyping of transgenic mice. *Physiol Behav* **73**(5): 731-744.

Stewart J, Badiani A (1993). Tolerance and sensitization to the behavioral effects of drugs. *Behav Pharmacol* **4**(4): 289-312.

Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF (2016). The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? *Neurochem Int* **99**: 110-132.

Stuchlik A, Radostova D, Hatalova H, Vales K, Nekovarova T, Koprivova J, *et al* (2016). Validity of quinpirole sensitization rat model of OCD: Linking evidence from animal and clinical studies. *Front Behav Neurosci* **10**: 209. Sullivan RM, Talangbayan H, Einat H, Szechtman H (1998). Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. *Neuroscience* **83**(3): 781-789.

Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, *et al* (1998). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. *Am J Psychiatry* **155**(2): 264-271.

Szechtman H, Ahmari SE, Beninger RJ, Eilam D, Harvey BH, Edemann-Callesen H, *et al* (2017). Obsessive-compulsive disorder: Insights from animal models. *Neurosci Biobehav Rev* **76**(Part B): 254-279.

Szechtman H, Culver K, Eilam D (1999). Role of dopamine systems in obsessivecompulsive disorder (OCD): implications from a novel psychostimulant-induced animal model. *Pol J Pharmacol* **51**(1): 55-61.

Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM (1994a). Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. *Pharmacology, biochemistry, and behavior* **48**(4): 921-928.

Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM (1994b). Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. *Pharmacology Biochemistry and Behavior* **48**: 921-928.

Szechtman H, Shivji S, Woody E (2014). Pathophysiology of Obsessive-Compulsive Disorder: Insights from Normal Function and Neurotoxic Effects of Drugs, Infection, and Brain Injury. In: Kostrzewa RM (ed). *Handbook of Neurotoxicity*. Springer New York, pp 2231-2253.

Szechtman H, Sulis W, Eilam D (1998). Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). *Behav Neurosci* **112**(6): 1475-1485.

Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D (1994c). Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism [published erratum appears in Psychopharmacology (Berl) 1994 Sep;116(1):124]. *Psychopharmacology (Berl)* **115**: 95-104.

Szechtman H, Woody E (2004). Obsessive-compulsive disorder as a disturbance of security motivation. *Psychol Rev* **111**(1): 111-127.

Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H (1997). Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. *Psychopharmacology (Berl)* **134**(2): 193-200.

Szumlinski KK, Goodwill AM, Szechtman H (2000). Locomotor sensitization to quinpirole in rats: effects of drug abstinence and sex. *Psychopharmacology (Berl)* **152**(3): 304-311.

Torrey EF, Bartko JJ, Lun ZR, Yolken RH (2007). Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. *Schizophr Bull* **33**(3): 729-736.

Tucci MC, Dvorkin-Gheva A, Graham D, Amodeo S, Cheon P, Kirk A, *et al* (2013). Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). *Psychopharmacology (Berl)* **227**(2): 277-285.

Tucci MC, Dvorkin-Gheva A, Sharma R, Taji L, Cheon P, Peel J, *et al* (2014). Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD). *Psychopharmacology* (*Berl*) **231**(18): 3707-3718.

Turna J, Grosman Kaplan K, Anglin R, Van Ameringen M (2016). "What's Bugging the Gut in OCD?" a Review of the Gut Microbiome in Obsessive-Compulsive Disorder. *Depress Anxiety* **33**(3): 171-178.

Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI (2009). The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* **1**(6): 6ra14.

Vissing J, Iwamoto GA, Rybicki KJ, Galbo H, Mitchell JH (1989a). Mobilization of glucoregulatory hormones and glucose by hypothalamic locomotor centers. *The American journal of physiology* **257**(5 Pt 1): E722-728.

Vissing J, Wallace JL, Scheurink AJ, Galbo H, Steffens AB (1989b). Ventromedial hypothalamic regulation of hormonal and metabolic responses to exercise. *The American journal of physiology* **256**(5 Pt 2): R1019-1026.

Vital M, Howe AC, Tiedje JM (2014). Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. *MBio* **5**(2): e00889.

Wang J, Linnenbrink M, Kunzel S, Fernandes R, Nadeau MJ, Rosenstiel P, *et al* (2014). Dietary history contributes to enterotype-like clustering and functional metagenomic content in the intestinal microbiome of wild mice. *Proc Natl Acad Sci U S A* **111**(26): E2703-2710.

Westenberg HG, Fineberg NA, Denys D (2007). Neurobiology of obsessive-compulsive disorder: serotonin and beyond. *CNS Spectrums* **12**(2 Suppl 3): 14-27.

Whelan FJ, Verschoor CP, Stearns JC, Rossi L, Luinstra K, Loeb M, *et al* (2014). The loss of topography in the microbial communities of the upper respiratory tract in the elderly. *Annals of the American Thoracic Society* **11**(4): 513-521.

Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, *et al* (2011). Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. *PLoS One* **6**(9): e24585.

Winter C, Mundt A, Jalali R, Joel D, Harnack D, Morgenstern R, *et al* (2008). High frequency stimulation and temporary inactivation of the subthalamic nucleus reduce quinpirole-induced compulsive checking behavior in rats. *Exp Neurol* **210**(1): 217-228.

Wise RA, Leeb K (1993). Psychomotor-stimulant sensitization: a unitary phenomenon? *BehavPharmacol* **4**(4): 339-349.

Woo V, Alenghat T (2017). Host-microbiota interactions: epigenomic regulation. *Curr Opin Immunol* **44**: 52-60.

Woody EZ, Szechtman H (2005). Motivation, time course, and heterogeneity in obsessive-compulsive disorder: Response to Taylor, McKay, and Abramowitz (2005). *Psychol Rev* **112**(3): 658-661.

Woody EZ, Szechtman H (2011). Adaptation to potential threat: The evolution, neurobiology, and psychopathology of the security motivation system. *Neurosci Biobehav Rev* **35**(4): 1019-1033.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al (2011). Linking long-term dietary patterns with gut microbial enterotypes. *Science* **334**(6052): 105-108.

Ye Y (2011). Identification and Quantification of Abundant Species from Pyrosequences of 16S rRNA by Consensus Alignment. *Proceedings IEEE International Conference on Bioinformatics and Biomedicine* **2010**: 153-157.

Zadicario P, Ronen S, Eilam D (2007). Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: implications for OCD rituals and for exploration and navigation. *BMC Neurosci* **8**: 23.

Zhu X, Han Y, Du J, Liu R, Jin K, Yi W (2017). Microbiota-gut-brain axis and the central nervous system. *Oncotarget* **8**(32): 53829-53838.

FIGURE CAPTIONS

FIGURE 1

Effects of chronic treatment with quinpirole on the criteria measures for compulsive checking. See Table 1 for parameters of the indicated regression lines. Each symbol is the mean value for the indicated dependent variable at the indicated injection obtained from all rats showing a value. Regression lines were computed from the regression parameters of each individual rat as described in Methods. *Open circles*, Saline control group injected repeatedly with saline; *open squares*, Quinpirole group injected repeatedly with saline; *open squares*, Quinpirole group injected repeatedly with saline; *open squares*, Quinpirole group injected repeatedly with quinpirole (0.25 mg/kg). The corresponding regression lines are: *thin solid line*, saline group; *thick solid line*, quinpirole group. *Light gray vertical rectangle* indicates that the groups evaluated at injection 9 were statistically different (p<0.05, *t*-tests).

FIGURE 2

Effects of chronic treatment with quinpirole on the routes of travel (a) and on measures of distance travelled (b), 2 standard deviational ellipse (c) and path stereotypy (d). Routes of travel are shown as path plots for a representative rat treated with saline (top row) or quinpirole (bottom row). Locomotor trajectories during the entire 55 min session for injections 1 to 9 are shown. Each line represents a trajectory of locomotion and the density of trajectory lines corresponds to amount of locomotion. Gray squares indicate locations of the four objects in the open field. *Open circles*, Saline control group injected repeatedly with saline; *open squares*, Quinpirole group injected repeatedly with quinpirole (0.25 mg/kg). The corresponding regression lines are: *thin solid line*, saline group; *thick solid line*, quinpirole group; see Table 1 for parameters of the regression lines. *Light gray vertical rectangle* indicates that the groups evaluated at injection 9 were statistically different (p<0.05, *t*-tests).

FIGURE 3

Two examples of OTUs from the family *Lachnospiraceae* that changed with repeated injections of quinpirole. Data are from Table 2.







Lachnospiraceae



Compulsive Checking and	Regression	Gro	up ²	Group Effect ³			
Locomotion Measures	Parameters ¹	Saline	Quinpirole	F(1,29)	Р	$\eta_{ m p}{}^2$	
Frequency of checking	intercept	14.03 ±2.95	25.91 ±3.05	7.847	0.009	0.213	
	slope	-0.42 ± 0.94	4.56 ±0.97	13.620	0.001	0.320	
Length of check (log s)	intercept	1.49±0.15	1.75 ±0.15	1.505	0.230	0.049	
	slope	0.04 ± 0.03	- 0.06 ±0.03	7.278	0.012	0.201	
Recurrence time of checking (s)	intercept	115.18 ±18.50	50.39 ±19.11	5.932	0.021	0.170	
	slope	4.71±2.77	-0.09±2.86	1.452	0.238	0.048	
# of stops before returning to check	intercept	4.09 ±0.29	2.56 ±0.30	13.896	0.001	0.324	
	slope	0.12 ± 0.05	0.01 ± 0.06	1.840	0.185	0.060	
Time to next checking bout (log s)	intercept	2.62 ±0.23	2.88 ±0.20	0.741	0.400	0.036	
	slope	0.05 ± 0.03	-0.06 ±0.03	7.694	0.012	0.278	
Distance (m)	intercept	41.48 ±11.96	49.66 ±12.35	0.227	0.638	0.008	
	slope	0.55 ± 3.31	21.26 ±3.42	18.902	0.000	0.395	
2SDE	intercept	4.92 ±0.35	2.06 ±0.36	32.788	0.000	0.531	
	slope	0.12 ±0.05	0.21 ±0.05	1.673	0.206	0.055	
Path stereotypy (ratio)	intercept	2.11 ±0.17	2.83 ±0.18	8.614	0.006	0.229	
	slope	0.01 ± 0.04	0.09 ±0.04	2.524	0.123	0.080	

Table 1Parameters of regression lines in figures 1 and 2 for compulsive checking and for measures of locomotion.

¹ Estimates of group slope and intercept are means (and SEM) of individual rat regression parameters fitted to the dependent variable data across injections 1 to 9. Values in bold font are significantly different from 0.

² Saline group (n=16) refers to control group that was injected chronically with saline; Quinpirole group (n=15) refers to rats that were injected chronically with quinpirole (0.25 mg/kg).

³ Groups were evaluated using a 1-way analysis of variance and the obtained F values, statistical significance and partial eta squared values (η_{P^2}) are indicated. Degrees of freedom for *Time to next checking bout (log s)* were 1 and 20. Significant *P* values (p<0.05) are indicated by italic font.

			Gro	up ⁴	Drug Effect⁵		Injection Effect ⁵			Drug x Injection Interaction ⁵			
Taxonomy ¹	OTU #2	Injection ³	Saline	Quinpirole	F(1,28)	Р	η_{p}^{2}	F(2,56)	Р	η_{p}^{2}	F(2,56)	Р	η_{p}^{2}
Firmicutes/Clostridia													
oClostridiales; fClostridiaceae; gSarcina	7	1	847.3 ± 233.0	1201.4 ± 233.0	6.285	0.018	0.183	3.822	0.028	0.120	3.315	0.044	0.106
		5	839.5 ± 878.6	3896.0±878.6									
		9	1170.6±734.0	3252.6±734.0									
oClostridiales	26	1	154.0 ± 61.0	116.5 ± 61.0	9.519	0.005	0.254	3.957	0.025	0.124	4.937	0.011	0.150
		5	930.5 ± 164.0	91.7±164.0									
		9	463.1 ± 161.3	258.3±161.3									
oClostridiales; fRuminococcaceae; g	44	1	56.2 ± 13.7	33.4±13.7	2.662	0.114	0.087	16.104	0.000	0.365	3.978	0.024	0.124
		5	87.3 ± 26.9	143.9 ± 26.9									
		9	113.9 ± 28.1	200.2 ± 28.1									
oClostridiales; fLachnospiraceae	101	1	4.7 ± 5.5	20.7 ± 5.5	9.627	0.004	0.256	10.336	0.000	0.270	8.472	0.001	0.232
		5	24.5 ± 8.9	23.9 ± 8.9									
		9	17.6 ± 14.7	92.5±14.7									
oClostridiales; fRuminococcaceae; gOscillospira	118	1	4.4 ± 1.4	5.3 ± 1.4	5.235	0.030	0.158	4.680	0.013	0.143	3.179	0.049	0.102
		5	6.5 ± 19.0	39.3 ± 19.0									
		9	11.6 ± 18.4	80.7±18.4									
oClostridiales; fLachnospiraceae; gMoryella	140	1	5.5 ± 4.3	12.9 ± 4.3	11.131	0.002	0.284	10.492	0.000	0.273	3.212	0.048	0.103
		5	8.2 ± 4.7	21.3 ± 4.7									
		9	17.5 ± 9.2	54.3±9.2									
oClostridiales; fLachnospiraceae; g	156	1	1.1 ± 0.6	1.5 ± 0.6	6.899	0.014	0.198	7.325	0.001	0.207	5.691	0.006	0.169
		5	2.7 ± 2.7	6.3 ± 2.7									
		9	6.5 ± 20.3	77.9 ± 20.3									
	176	1	7.1 ± 3.4	6.4 ± 3.4	7.684	0.010	0.215	1.223	0.302	0.042	3.896	0.026	0.122
		5	11.8 ± 4.2	4.5 ± 4.2									
		9	28.7 ± 7.4	0.1 ± 7.4									
	177	1	0.7 ± 1.4	4.3 ± 1.4	8.063	0.008	0.224	8.792	0.000	0.239	6.424	0.003	0.187
		5	1.7 ± 4.9	16.9 ± 4.9									
		9	4.5 ± 12.4	53.4±12.4									
oClostridiales; f; g	197	1	9.5 ± 2.1	14.5 ± 2.1	0.020	0.890	0.001	4.192	0.020	0.130	7.040	0.002	0.201
		5	17.2 ± 2.0	10.3 ± 2.0									
		9	7.6 ± 1.9	10.3 ± 1.9									

Table 2OTUs where a 2x3 ANOVA yielded a statistically significant Drug by Injection interaction

o Clostridiales: f Ruminococcaceae	252	1	43+15	45+15	7 951	0.009	0 221	6 3 2 2	0.003	0 184	3 3 2 8	0.043	0 106
	252	5	4.3 ± 1.3 2.3 ± 1.3	4.3 ± 1.3 7.7 ± 1.3	7.551	0.005	0.221	0.522	0.005	0.104	5.520	0.045	0.100
		9	5.7 ± 3.4	17.0±3.4									
oClostridiales; fRuminococcaceae; g	262	1	0.1 ± 0.9	2.9±0.9	8.998	0.006	0.243	4.390	0.017	0.136	4.547	0.015	0.140
		5	0.0 ± 3.0	12.4 ± 3.0									
		9	0.0 ± 5.1	18.9±5.1									
oClostridiales; fLachnospiraceae; g	375	1	0.1 ± 0.0	0.0 ± 0.0	6.208	0.019	0.181	4.089	0.022	0.127	4.199	0.020	0.130
		5	0.1 ± 2.0	5.8±2.0									
		9	0.0 ± 2.1	7.5 ± 2.1									
oClostridiales; fRuminococcaceae	433	1	1.1 ± 0.5	1.6 ± 0.5	18.831	0.000	0.402	1.387	0.258	0.047	6.327	0.003	0.184
		5	0.7 ± 0.6	3.1±0.6									
		9	0.1 ± 0.7	4.5 ± 0.7									
oClostridiales	454	1	0.2 ± 0.2	0.5 ± 0.2	6.647	0.015	0.192	5.232	0.008	0.157	3.216	0.048	0.103
		5	0.4 ± 0.7	2.7 ± 0.7									
		9	0.6 ± 0.9	3.5 ± 0.9									
oClostridiales; fRuminococcaceae	462	1	0.0 ± 0.1	0.3 ± 0.1	9.140	0.005	0.246	8.857	0.000	0.240	5.426	0.007	0.162
		5	0.3 ± 0.5	2.1 ± 0.5									
		9	0.6 ± 1.1	5.1 ± 1.1									
oClostridiales; fClostridiaceae	484	1	0.2 ± 0.2	0.4 ± 0.2	6.805	0.014	0.196	7.008	0.002	0.200	4.447	0.016	0.137
		5	0.4 ± 0.6	1.8 ± 0.6									
		9	0.5 ± 0.7	3.3 ± 0.7									
oClostridiales; fLachnospiraceae; g	550	1	0.0 ± 0.0	0.1 ± 0.0	4.996	0.034	0.151	7.183	0.002	0.204	3.692	0.031	0.117
		5	0.1 ± 0.1	0.3 ± 0.1									
		9	0.6 ± 1.0	3.5 ± 1.0									
oClostridiales; fLachnospiraceae	565	1	0.1 ± 0.1	0.2 ± 0.1	8.082	0.008	0.224	10.698	0.000	0.276	5.012	0.010	0.152
		5	0.1 ± 0.3	1.0 ± 0.3									
		9	0.5 ± 0.5	2.5 ± 0.5									
	636	1	0.1 ± 0.2	0.3 ± 0.2	2.773	0.107	0.090	9.414	0.000	0.252	4.383	0.017	0.135
		5	0.3 ± 0.2	0.3 ± 0.2									
		9	1.9 ± 0.4	0.6 ± 0.4									
oClostridiales; fClostridiaceae; gClostridium	796	1	0.1 ± 0.1	0.2 ± 0.1	8.313	0.007	0.229	5.424	0.007	0.162	3.958	0.025	0.124
		5	0.1 ± 0.2	0.6 ± 0.2									
		9	0.1 ± 0.2	1.1 ± 0.2									
oClostridiales; fRuminococcaceae; gClostridium	813	1	0.1 ± 0.1	0.2 ± 0.1	1.800	0.190	0.060	5.224	0.008	0.157	4.388	0.017	0.135
		5	0.1 ± 0.1	0.1 ± 0.1									

		9	0.7 ± 0.2	0.2 ± 0.2									
Tenericutes/Mollicutes													
oRF39; f; g	60	1	50.3 ± 21.2	46.6±21.2	3.139	0.087	0.101	0.679	0.511	0.024	3.765	0. <i>029</i>	0.119
		5	65.9 ± 40.2	75.0 ± 40.2									
		9	192.5 ± 56.3	0.1 ± 56.3									
Proteobacteria/Betaproteobacteria													
oBurkholderiales; fAlcaligenaceae; g	68	1	75.1 ± 23.5	101.6 ± 23.5	1.157	0.291	0.040	6.631	0.003	0.191	3.545	0.036	0.112
		5	53.6±8.4	20.5 ± 8.4									
		9	80.1 ± 11.4	36.9 ± 11.4									
Deferribacteres/Deferribacteres													
oDeferribacterales; fDeferribacteraceae; gMucispirillum	365	1	1.9 ± 1.3	1.3 ± 1.3	3.534	0.071	0.112	2.514	0.090	0.082	3.729	0.030	0.118
		5	1.5 ± 0.7	1.9 ± 0.7									
		9	1.1 ± 2.3	8.3±2.3									

¹Bold font indicates the phylum/class. Taxa in the designated phylum/class are indented in successive rows and are identified with the prefix "o_" (order), "f_" (family), and "g_" (genus).

² Operational Taxonomic Unit (OTU) assigned the taxonomic identification indicated in the left column. OTU numerals correspond to the rank order of counts in bacterial clusters (from highest to lowest counts). Table is sorted from lowest to highest OTU within phylum/cluster.

³ Injection is the number of administrations of saline or quinpirole received at the indicated open field test. Injection is a repeated measures factor with 3 levels (injection 1 vs injection 5 vs injection 9).

⁴ Saline refers to the control group that was injected chronically with saline, and Quinpirole is the experimental group treated chronically with quinpirole (0.25 mg/kg); they constitute the chronic drug treatment factor, with two levels (Saline vs Quinpirole). Values are the adjusted marginal means and 1 SE from the Drug by Injection ANOVA. Numbers are the counts in the rarefied OTU table with 43335 reads/sample and index a measure of the abundance of bacteria in the assigned OTU.

⁵ Groups were evaluated using a drug-by-injection analysis of variance and the F values obtained, statistical significance, and partial eta squared values (ηp^2) are indicated. Significant differences (P < 0.05) are marked in italic font.

Dear Dr Willner

Thank you very much for the encouraging and helpful comments of the reviewers. We have incorporated most of the suggestions made by the reviewers:

Reviewer 1:

- Reviewer suggests that it may be useful to present additional analyses of the microbiota data and in particular by profiling at higher taxonomic classifications. Although we did do such analyses they were not very revealing and helpful, probably because the changes we report are confined to relatively few OTUs and thus likely overshadowed at grosser levels of analysis. Moreover, we are really interested in changes that appear as a result of several injections of quinpirole and those are difficult to discern from the effects of time in the type of analyses that the reviewer suggests. Hence, we did not include such analyses in the paper. However, we are depositing the raw sequence data in the NCBI data base and thus they are available to additional analyses by any interested researcher.
- 2. Reviewer suggests that we relate our quinpirole findings to other studies where the effects of dopaminergic drugs on gut microbiota were investigated, and the reviewer points to 3 such studies. We thank the reviewer for the suggestion and pointing us to those studies. We did not find a way to relate our findings to the results of those studies that used dopamine blockers; the third study where cocaine was used did not measure gut microbiota. However, following up on the reviewer's suggestion we found a recent study examining the effects amphetamine on gut microbiota and we included it in the revised ms. Moreover, we also included in the revised ms a comparison to studies of Parkinson patients where the microbiota findings were in the opposite direction to the quinpirole results (page 12, 2nd paragraph of the Discussion).
- 3. Reviewer did not consider that the link with T. gondii was very convincing in our exposition of the "infection model". We have re-written the sections describing the plausible models to make them clearer. In the revised description the model is called "MODEL OF MICROBIOTA STIMULATING BEHAVIOR" and we believe presents a more convincing picture of the plausible linkage between microbiota and behavior considered in the literature (pages 13-15, section "Two perspectives" was reworded substantially).

Reviewer 2.

- 1. Reviewer suggests that we should be more consistent and use "locomotor sensitization" rather than just "sensitization" throughout the ms. We agree and made those changes in the revised ms.
- Reviewer points to an unexplained XXX in the Results section. We apologize for this mistake. The XXX was a placeholder to input the appropriate value but clearly I missed doing this before submitting the ms. The appropriate value (4313) is now indicated (page 11, 3rd paragraph).
- Reviewer suggests that we elaborate more on our findings and in particular on the functions of the altered microbiota. We thank the reviewer for this suggestion and in the revised ms present more information (page 13, 2nd paragraph). We also expanded the following paragraph (page 13,

3rd paragraph) presenting the possible interpretations for the observed association between gut microbiota and behavior.

4. Reviewer found that the gray vertical rectangles were not clear in Figures 1 and 2. We made those rectangles darker and hopefully easier to see.

In addition to those changes we also revised Table 2 to make it clearer by providing more annotations and by presenting the data sorted by OTU rank as that gives a better picture of the size of the observed changes. We also made some stylistic changes on re-reading the ms.

As noted above, we are depositing the raw sequence data to NCBI database and that is indicated in the ms on page 6: "Raw sequence reads have been deposited in the NCBI Short Read Archive under BioProject xxxxxxxxx." That sentence is highlighted in yellow as the deposit is not yet complete and we do not have the actual project ID to include in the ms. However, the submission to NCBI should be completed in a few days and I can input the project ID at the page proofs stage or if a second revision of the ms is needed.

We thank again the reviewers and you for the comments on the ms and we trust that we have addressed all the issues.

With many thanks and best wishes

Henry Szechtman